Patent · US Active

Compositions and methods for inhibition of the JAK pathway

US8304422B2 · kind B2 · utility

26Cited by

7References

22Claims

0Family size

Assignee

Rigel Pharmaceuticals, Inc. · US

Inventors

Andy Atuegbu · Dublin, US
Vadim Markovtsov · San Mateo, US
Somasekhar Bhamidipati · Foster City, US
Rajinder Singh · Belmont, US
Vanessa Taylor · San Francisco, US
Sambaiah Thota · Fremont, US
Jeffrey Clough · Redwood City, US
David Carroll · San Francisco, US
Hui Li · Santa Clara, US
Robin Cooper · St. Augustine, US

Key dates

Filing date	Dec 13, 2010
Grant date	Nov 6, 2012
Priority date	—
Expiry date	Feb 3, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.